<DOC>
	<DOCNO>NCT00210522</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety novel compound RWJ-333369 reducing frequency seizures patient epilepsy .</brief_summary>
	<brief_title>An Open-Label Extension Study Effectiveness Safety Investigational Compound RWJ-333369 Patients With Epilepsy</brief_title>
	<detailed_description>333369EPY2006 open-label extension study follow double-blind study 333369EPY2003 . In open label study 333369EPY2006 , physician patient know name assign study medication . In double blind study 333369EPY2003 , neither physician patient know name assign study medication . Patients complete double-blind treatment phase study 333369EPY2003 eligible enter open-label extension study patient transition blind period open-label period carisbamate ( also refer RWJ-333369 ) . RWJ-333369 new chemical compound anticonvulsant activity currently investigation treatment epilepsy . Patients elect enter open-label extension phase supply open-label carisbamate ( RWJ-333369 ) blind study medication transition phase . During transition phase ( approximately 3 week length ) , patient 's dose double-blind study drug gradually reduce stop treatment open-label RWJ-333369 start . Throughout remainder open label extension phase , investigator allow make adjustment dosage schedule carisbamate , include independent adjustment morning evening dos , dosage 1,200 mg/day may exceed increase dosage must increments 200 mg/day . After 12 month participation open-label extension study , patient , judgment investigator , continue benefit treatment RWJ-333369 may continue receive drug follow clinic visit every 3 month RWJ 333369 available prescription program terminate sponsor . RWJ-333369 ( 100 , 300 , 800 , 1,600 milligram per day ) administer orally 2 equally divided dos 16 week double-blind treatment follow option continue RWJ-333369 treatment open-label study least 1 year , drug available production cease .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<criteria>Patients must complete Visit 8 ( Day 112 ) doubleblind treatment phase Study EPY2003 eligible entry openlabel treatment phase Study EPY2006 . Patients seizure quantitated accurately Patients history nonepileptic seizure , serious systemic disease , progressive neurologic disorder , major psychiatric disorder , status epilepticus past 3 month , vagal nerve stimulation discontinuation within past 3 month Patients history drug alcohol abuse within past 2 year Patients currently take felbamate , vigabatrin , tricyclic antidepressant patient pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>RWJ-333369</keyword>
	<keyword>Anticonvulsants</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Refractory partial epilepsy</keyword>
	<keyword>Seizure disorder</keyword>
	<keyword>Antiepileptic drug</keyword>
</DOC>